FI3904391T3 - Monoklonaaliset vasta-aineet c-Met:iä vastaan - Google Patents

Monoklonaaliset vasta-aineet c-Met:iä vastaan Download PDF

Info

Publication number
FI3904391T3
FI3904391T3 FIEP21171029.8T FI21171029T FI3904391T3 FI 3904391 T3 FI3904391 T3 FI 3904391T3 FI 21171029 T FI21171029 T FI 21171029T FI 3904391 T3 FI3904391 T3 FI 3904391T3
Authority
FI
Finland
Prior art keywords
cancer
antibody
bispecific antibody
treatment
antibody according
Prior art date
Application number
FIEP21171029.8T
Other languages
English (en)
Finnish (fi)
Inventor
Joost Neijssen
Goeij Bart De
Den Brink Edward Van
Aran Labrijn
Rene Hoet
Janine Schuurman
Paul Parren
De Winkel Jan Van
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab As filed Critical Genmab As
Application granted granted Critical
Publication of FI3904391T3 publication Critical patent/FI3904391T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Inorganic Chemistry (AREA)
FIEP21171029.8T 2010-03-10 2011-03-10 Monoklonaaliset vasta-aineet c-Met:iä vastaan FI3904391T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31262210P 2010-03-10 2010-03-10
DKPA201000191 2010-03-10
DKPA201000862 2010-09-24

Publications (1)

Publication Number Publication Date
FI3904391T3 true FI3904391T3 (fi) 2024-10-02

Family

ID=44342987

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP21171029.8T FI3904391T3 (fi) 2010-03-10 2011-03-10 Monoklonaaliset vasta-aineet c-Met:iä vastaan

Country Status (26)

Country Link
US (6) US9068011B2 (enExample)
EP (4) EP3511342B1 (enExample)
JP (4) JP6055312B2 (enExample)
KR (2) KR101814571B1 (enExample)
CN (2) CN103003307B (enExample)
AU (4) AU2011226103C1 (enExample)
BR (1) BR112012022672B1 (enExample)
CA (3) CA3157780A1 (enExample)
DK (1) DK3904391T3 (enExample)
EA (1) EA201201273A1 (enExample)
ES (1) ES2993335T3 (enExample)
FI (1) FI3904391T3 (enExample)
HR (1) HRP20241246T1 (enExample)
HU (1) HUE068433T2 (enExample)
IL (1) IL221408B (enExample)
LT (1) LT3904391T (enExample)
MX (1) MX340295B (enExample)
NZ (1) NZ602294A (enExample)
PH (1) PH12012501793B1 (enExample)
PL (1) PL3904391T3 (enExample)
PT (1) PT3904391T (enExample)
RS (1) RS66008B1 (enExample)
SG (2) SG183190A1 (enExample)
SI (1) SI3904391T1 (enExample)
SM (1) SMT202400403T1 (enExample)
WO (1) WO2011110642A2 (enExample)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101814571B1 (ko) 2010-03-10 2018-01-04 젠맵 에이/에스 Ｃ―ｍｅｔ에 대한 모노클로날 항체
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
PL2723769T5 (pl) 2011-06-23 2022-10-17 Ablynx Nv Techniki przewidywania, wykrywania i redukcji niespecyficznej interferencji białka w testach z udziałem pojedynczych domen zmiennych immunoglobuliny
EP4218933A1 (en) 2011-06-23 2023-08-02 Ablynx NV Serum albumin binding proteins
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
EP2758430A4 (en) 2011-09-20 2015-06-03 Lilly Co Eli ANTI-C-MET ANTIBODY
JP6219287B2 (ja) * 2011-09-30 2017-10-25 アブリンクス エン．ヴェー． ｃ−Ｍｅｔに関連する生物学的物質
US9346884B2 (en) * 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
KR20130037153A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 항 ｃ-Ｍｅｔ 항체 및 그의 용도
EP2776061B1 (en) * 2011-11-07 2019-08-14 MedImmune, LLC Multispecific and multivalent binding proteins and uses thereof
CN104066748A (zh) 2011-11-21 2014-09-24 霍夫曼-拉罗奇有限公司 抗c-met抗体的纯化
EP2785741A1 (en) * 2011-12-02 2014-10-08 Cancer Research Technology Limited Antibodies against hgf - receptor and uses
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
CA2877573A1 (en) * 2012-06-21 2013-12-27 Sorrento Therapeutics, Inc. Antigen binding proteins that bind c-met
SG11201408646VA (en) 2012-07-06 2015-01-29 Genmab Bv Dimeric protein with triple mutations
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
DK2922872T3 (da) * 2012-11-21 2019-01-02 Janssen Biotech Inc Bispecifikke egfr/c-met-antistoffer
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
KR20210096697A (ko) 2013-01-10 2021-08-05 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
JP2014157056A (ja) * 2013-02-15 2014-08-28 Fujirebio Inc ｃ−ＭＥＴ遺伝子増幅細胞の検出方法
US9458245B2 (en) 2013-03-06 2016-10-04 Merrimack Pharmaceuticals, Inc. ANTI-C-MET tandem Fc bispecific antibodies
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US10214593B2 (en) 2013-04-02 2019-02-26 Samsung Electronics Co., Ltd. Anti-idiotype antibody against anti-c-MET antibody
EP2787008B1 (en) * 2013-04-02 2019-09-04 Samsung Electronics Co., Ltd. Anti-idiotype antibody against anti-C-met antibody
EP3057608B1 (en) 2013-10-14 2025-12-10 Janssen Biotech, Inc. Cysteine engineered fibronectin type iii domain binding molecules
EA039356B1 (ru) * 2013-10-18 2022-01-18 Янссен Байотек, Инк. БИСПЕЦИФИЧЕСКИЕ К EGFR/c-Met АНТИТЕЛА
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
HRP20241036T1 (hr) 2013-11-21 2024-11-08 Genmab A/S Liofilizirana formulacija konjugata protutijelo-lijek
CN105085680A (zh) * 2014-05-23 2015-11-25 复旦大学 人源化抗PD-1及c-MET双特异性抗体及其制备方法和应用
KR101615619B1 (ko) 2014-08-07 2016-04-26 주식회사 파멥신 c-Met 특이적 인간 항체 및 그 제조방법
CN107001471B (zh) 2014-09-16 2022-01-18 西福根有限公司 抗met抗体和组合物
EP3215175A4 (en) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
IL284985B2 (en) 2015-02-18 2023-03-01 Enlivex Therapeutics R& D Ltd Combined immunotherapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
CA2982452A1 (en) 2015-04-21 2016-10-27 Enlivex Therapeutics Ltd. Therapeutic pooled blood apoptotic cell preparations and uses thereof
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
EP3324996A4 (en) * 2015-07-22 2019-04-17 Scholar Rock, Inc. GDF11 BINDING PROTEINS AND USES THEREOF
PL3350220T3 (pl) 2015-09-15 2022-01-03 Scholar Rock, Inc. Przeciwciała przeciwko pro/latentnej miostatynie i ich zastosowania
CN108350078A (zh) * 2015-11-03 2018-07-31 默克专利股份公司 用于提高肿瘤选择性和抑制的双特异性抗体及其用途
AU2017206069A1 (en) 2016-01-08 2018-07-19 Scholar Rock, Inc. Anti-pro/latent myostatin antibodies and methods of use thereof
US11730761B2 (en) 2016-02-18 2023-08-22 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
PT3368069T (pt) 2016-06-13 2020-11-11 Scholar Rock Inc Uso de inibidores da miostatina e terapias de combinação
WO2017223180A2 (en) 2016-06-21 2017-12-28 Janssen Biotech, Inc. Cysteine engineered fibronectin type iii domain binding molecules
RU2747557C2 (ru) 2016-08-02 2021-05-06 Вэксинекс, Инк. Улучшенные способы получения библиотек полинуклеотидов в вирусах осповакцины/эукариотических клетках
TWI770065B (zh) * 2016-09-29 2022-07-11 日商田邊三菱製藥股份有限公司 Ｃｍｅｔ單株結合劑、其藥物複合體及其用途
TWI782930B (zh) * 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
RU2759952C2 (ru) 2016-12-14 2021-11-19 Янссен Байотек, Инк. Cd8a-связывающие домены типа iii фибронектина
TW201825515A (zh) * 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
SI3565592T1 (sl) 2017-01-06 2023-05-31 Scholar Rock, Inc. Zdravljenje presnovnih bolezni z zaviranjem aktivacije miostatina
CN106831995A (zh) * 2017-03-31 2017-06-13 北京百特美博生物科技有限公司 新型双特异性抗体及其用途
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
AU2018278730B2 (en) * 2017-05-30 2021-02-04 Chong Kun Dang Pharmaceutical Corp. A novel anti-c-Met antibody and use thereof
US11525002B2 (en) 2017-10-11 2022-12-13 Board Of Regents, The University Of Texas System Human PD-L1 antibodies and methods of use therefor
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
AU2019239568B2 (en) 2018-03-23 2025-09-11 Board Of Regents, The University Of Texas System Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use therefor
EP3768726B1 (en) 2018-03-23 2024-10-30 Board of Regents, The University of Texas System Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
CA3092695A1 (en) 2018-03-23 2019-09-26 Board Of Regents, The University Of Texas System Human pd-l2 antibodies and methods of use therefor
TW202010755A (zh) 2018-05-07 2020-03-16 丹麥商珍美寶股份有限公司 使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法
CN112513281B (zh) * 2018-07-10 2024-11-08 基因药物株式会社 抗肿瘤组合物
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
KR102396194B1 (ko) * 2018-12-07 2022-05-10 서울대학교 산학협력단 항 c-Met 아고니스트 항체 및 이의 용도
KR102433184B1 (ko) * 2018-12-07 2022-08-17 서울대학교 산학협력단 항 c-Met 아고니스트 항체 및 이의 용도
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
TWI845724B (zh) * 2019-07-19 2024-06-21 大陸商上海藥明合聯生物技術有限公司 用於偶聯的多肽複合物及其應用
WO2021022304A2 (en) 2019-07-30 2021-02-04 Qlsf Biotherapeutics, Inc. MULTISPECIFIC BINDING COMPOUNDS THAT BIND TO LRRC15 AND CD3ε
WO2021055350A1 (en) 2019-09-16 2021-03-25 Regeneron Pharmaceuticals, Inc. Radiolabeled met binding proteins for immuno-pet imaging
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
US12491255B2 (en) 2019-10-14 2025-12-09 Aro Biotherapeutics Company EPCAM binding fibronectin type III domains
US11628222B2 (en) 2019-10-14 2023-04-18 Aro Biotherapeutics Company CD71 binding fibronectin type III domains
CN111171147B (zh) * 2020-02-11 2021-07-20 北京康普美特创新医药科技有限责任公司 一种抗补体c3分子的全人源单克隆抗体及应用
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
CN111620944B (zh) * 2020-06-01 2023-03-21 长春师范大学 一种全人源化抗乙肝病毒单克隆抗体、制备方法及其应用
CN112625131B (zh) * 2020-08-10 2021-08-17 北京鼎成肽源生物技术有限公司 抗人c-Met人鼠嵌合单克隆抗体及其应用
WO2022152289A1 (en) * 2021-01-18 2022-07-21 Wuxi Biologics (Shanghai) Co., Ltd. An engineered antibody and antibody-drug conjugates comprisign same
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains
CA3215367A1 (en) 2021-04-14 2022-10-20 Swapnil Kulkarni Fn3 domain-sirna conjugates and uses thereof
EP4359446A4 (en) * 2021-06-25 2025-05-21 Academia Sinica ANTICANCER COMBINATION THERAPY BASED ON AN INHIBITOR OF EPITHELIAL CELL ADHESION MOLECULES (EPCAM) AND A HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR) INHIBITOR
CN113621058B (zh) * 2021-08-19 2023-05-23 中国科学院微生物研究所 黄热病毒抗体及其应用
CA3230934A1 (en) * 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
CN116178530A (zh) * 2021-09-26 2023-05-30 上海君实生物医药科技股份有限公司 抗体在治疗SARS-CoV-2感染的用途
CN116725960A (zh) * 2022-03-11 2023-09-12 上海君实生物医药科技股份有限公司 新型冠状病毒抗体药物组合物及其用途
US20250223366A1 (en) 2022-04-02 2025-07-10 Biotheus Inc. Monoclonal antibodies and bispecific antibody against c-met
AU2023317484A1 (en) 2022-07-30 2025-03-13 Pinetree Therapeutics, Inc. Compositions for targeted lysosomal degradaton and methods of use thereof
KR20250122524A (ko) 2022-12-22 2025-08-13 스칼러 락, 인크. 미오스타틴 활성화의 선택적이고 강력한 억제 항체
CN120603850A (zh) * 2023-01-19 2025-09-05 广州百济神州生物制药有限公司 抗cmet抗体及使用方法
TW202506733A (zh) 2023-06-12 2025-02-16 美商安進公司 淋巴毒素β受體促效劑結合蛋白
WO2025180462A1 (zh) * 2024-03-01 2025-09-04 苏州康宁杰瑞生物科技有限公司 双功能融合蛋白

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077A (en) 1849-01-30 Improved hinged claw-wrench
US835A (en) 1838-07-12 X i i i x
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5362716A (en) 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
WO1991009974A1 (en) 1989-12-27 1991-07-11 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Diagnostic probe for detecting human stomach cancer
US5648273A (en) 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU650292B2 (en) 1990-09-14 1994-06-16 United States of America, as represented by the Secretary, U.S. Department of Commerce, The A non-mitogenic competitive HGF antagonist
US6566098B1 (en) 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
DE69224906T2 (de) 1991-07-08 1998-10-29 Univ Massachusetts Thermotropes flüssig-kristallines segment-blockcopolymer
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU4645293A (en) 1992-06-26 1994-01-24 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The The met proto-oncogene and a method for predicting breast cancer progression
DE69334159D1 (de) 1992-09-18 2007-09-13 Us Gov Health & Human Serv Medizinische Verwendung eines Antikörpers oder eines Antikörperfragments gegen die extrazelluläre Domäne von Met zur Prevention von Metastasen
US5361922A (en) 1993-04-02 1994-11-08 Beckman Instruments, Inc. Centrifuge tubes with snap plugs
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5646036A (en) 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
WO1999050392A1 (en) 1998-03-31 1999-10-07 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
DE60013773T2 (de) 1999-02-03 2005-11-10 Biosante Pharmaceuticals, Inc. Methoden zur Herstellung von therapeutischen Kalziumphosphat Partikeln
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
ATE384744T1 (de) 1999-07-29 2008-02-15 Medarex Inc Menschliche antikörper gegen her2/neu
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
EP1355921A2 (en) 2000-06-29 2003-10-29 North Shore-Long Island Jewish Health System Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
US6713055B2 (en) 2000-11-27 2004-03-30 Geron Corporation Glycosyltransferase vectors for treating cancer
KR100857943B1 (ko) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
WO2002102973A2 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
WO2003048328A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
WO2003057155A2 (en) 2001-12-27 2003-07-17 Van Andel Research Institute Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
EP1592713A2 (en) 2003-02-13 2005-11-09 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
ITMI20031127A1 (it) 2003-06-05 2004-12-06 Uni Degli Studi Del Piemont E Orientale Am Anticorpi anti-hgf-r e loro uso
ATE425463T1 (de) 2003-06-06 2009-03-15 Genentech Inc Modulation der wechselwirkung zwischen hgf-beta- kette und c-met
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
SI2383295T1 (sl) 2003-12-10 2015-07-31 E.R. Squibb & Sons, L.L.C. Protitelesa IP-10 in njihova uporaba
CA2548282A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
EP2275448A3 (en) 2003-12-19 2013-02-06 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
CN102139106B (zh) 2004-05-27 2014-10-08 克鲁塞尔荷兰公司 能中和狂犬病病毒的结合分子及其应用
US7476724B2 (en) 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
EP1810979B1 (en) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
EP1868648B1 (en) 2005-03-25 2015-04-15 Genentech, Inc. Methods and compositions for modulating hyperstabilized c-met
KR20130114763A (ko) 2005-03-31 2013-10-18 더 제너럴 하스피탈 코포레이션 Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
ES2368864T3 (es) * 2006-02-06 2011-11-23 Metheresis Translational Research Sa Anticuerpos monoclonales anti-met, sus fragmentos y vectores para el tratamiento de tumores y productos correspondientes.
BRPI0709917A2 (pt) * 2006-03-30 2011-07-05 Novartis Ag composições e métodos de uso para anticorpos de c-met
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
MX2009009926A (es) * 2007-03-13 2010-03-15 Univ Zuerich Anticuerpo tumor-especifico humano monoclonal.
CA2688275A1 (en) 2007-05-31 2008-12-04 Genmab A/S Stable igg4 antibodies
US20080300108A1 (en) 2007-05-31 2008-12-04 Eybergen William N Torque transfer device and system
US20100325744A1 (en) * 2007-05-31 2010-12-23 Genmab A/S Non-glycosylated recombinant monovalent antibodies
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US9693539B2 (en) 2007-08-10 2017-07-04 E. R. Squibb & Sons, L.L.C. HCO32 and HCO27 and related examples
AU2009221808A1 (en) * 2008-03-06 2009-09-11 Genentech, Inc. Combination therapy with c-met and EGFR antagonists
CA2723197C (en) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US8455623B2 (en) 2008-05-21 2013-06-04 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
BRPI0919840B1 (pt) 2008-10-01 2023-02-28 Amgen Research (Munich) Gmbh Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
AR074438A1 (es) 2008-12-02 2011-01-19 Pf Medicament Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal
WO2010064089A1 (en) 2008-12-02 2010-06-10 Pierre Fabre Medicament Novel anti-cmet antibody
WO2010064090A1 (en) 2008-12-02 2010-06-10 Pierre Fabre Medicament Process for the modulation of the antagonistic activity of a monoclonal antibody
AR074439A1 (es) 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
KR101814571B1 (ko) 2010-03-10 2018-01-04 젠맵 에이/에스 Ｃ―ｍｅｔ에 대한 모노클로날 항체
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
DK2922872T3 (da) * 2012-11-21 2019-01-02 Janssen Biotech Inc Bispecifikke egfr/c-met-antistoffer

Also Published As

Publication number Publication date
JP6348541B2 (ja) 2018-06-27
EP3904391A1 (en) 2021-11-03
KR20130012128A (ko) 2013-02-01
ES2993335T3 (en) 2024-12-27
JP6697027B2 (ja) 2020-05-20
RS66008B1 (sr) 2024-10-31
MX340295B (es) 2016-07-05
US20170320962A1 (en) 2017-11-09
WO2011110642A2 (en) 2011-09-15
EP4483963A3 (en) 2025-09-24
EP3904391B1 (en) 2024-07-10
WO2011110642A3 (en) 2012-07-05
US20240084036A1 (en) 2024-03-14
AU2016200093A1 (en) 2016-02-04
IL221408B (en) 2020-09-30
IL221408A0 (en) 2012-10-31
AU2011226103A1 (en) 2012-09-27
AU2011226103C1 (en) 2016-04-28
CA3157780A1 (en) 2011-09-15
JP2017008041A (ja) 2017-01-12
CA2791863A1 (en) 2011-09-15
CN103003307A (zh) 2013-03-27
CA3254586A1 (en) 2025-11-29
US20150329642A1 (en) 2015-11-19
AU2017265061A1 (en) 2017-12-14
CN107739407B (zh) 2021-07-06
AU2011226103B2 (en) 2016-01-28
KR102059663B1 (ko) 2019-12-26
US11512140B2 (en) 2022-11-29
US9068011B2 (en) 2015-06-30
US20170313782A1 (en) 2017-11-02
US20130216548A1 (en) 2013-08-22
KR20180004292A (ko) 2018-01-10
EP3511342B1 (en) 2024-01-17
SI3904391T1 (sl) 2024-10-30
EP4483963A2 (en) 2025-01-01
LT3904391T (lt) 2024-10-10
EP2545077A2 (en) 2013-01-16
JP2018174937A (ja) 2018-11-15
DK3904391T3 (en) 2024-10-14
EP3511342A1 (en) 2019-07-17
JP2013529059A (ja) 2013-07-18
SG10201501767VA (en) 2015-05-28
MX2012009987A (es) 2012-11-30
HUE068433T2 (hu) 2024-12-28
CA2791863C (en) 2022-06-21
EA201201273A1 (ru) 2013-02-28
NZ602294A (en) 2015-04-24
US20200079872A1 (en) 2020-03-12
CN107739407A (zh) 2018-02-27
JP2020198874A (ja) 2020-12-17
SMT202400403T1 (it) 2024-11-15
PH12012501793B1 (en) 2018-08-24
BR112012022672A2 (pt) 2017-02-14
US9657107B2 (en) 2017-05-23
HRP20241246T1 (hr) 2024-12-06
SG183190A1 (en) 2012-09-27
BR112012022672B1 (pt) 2020-04-14
PH12012501793A1 (en) 2012-12-10
PT3904391T (pt) 2024-10-14
AU2019283925B2 (en) 2021-12-02
KR101814571B1 (ko) 2018-01-04
AU2017265061B2 (en) 2019-09-19
PL3904391T3 (pl) 2024-11-12
JP7034204B2 (ja) 2022-03-11
JP6055312B2 (ja) 2017-01-11
AU2019283925A1 (en) 2020-01-16
EP2545077B1 (en) 2018-10-31
CN103003307B (zh) 2017-08-11

Similar Documents

Publication Publication Date Title
FI3904391T3 (fi) Monoklonaaliset vasta-aineet c-Met:iä vastaan
Emanuel et al. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor
ES2387809T3 (es) Anticuerpo frente al receptor del factor de crecimiento epidérmico humano
JP2010531140A5 (enExample)
JP2018070648A5 (enExample)
RU2019113790A (ru) Анти-lag-3 антитела и их композиции
JP2018509175A5 (enExample)
BRPI0905076B8 (pt) anticorpo anti-receptor de il-6, gene e composição farmacêutica compreendendo o mesmo
EP2723771A1 (en) Serum albumin binding proteins
CA2595610A1 (en) Antibodies directed to angiopoietin-2 and uses thereof
WO2013110531A1 (en) Sequences directed against hepatocyte growth factor (hgf) and polypeptides comprising the same for the treatment of cancers and/or tumors
AU2013201422A1 (en) Sequences directed against hepatocyte growth factor (HFG) and polypeptides comprising the same for the treatment of cancers and/or tumors
RU2012107286A (ru) Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2
RU2013104830A (ru) Лечение рака при помощи направленных на мишень антител in vivo
RU2012137498A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
JP2014530215A5 (enExample)
US9943537B2 (en) Antitumor agent and antitumor effect enhancer
JP2008508858A5 (enExample)
JP2017534259A5 (enExample)
JP2013534515A5 (ja) 受容体型チロシンキナーゼｃ−Ｍｅｔに対する抗体
RU2016136527A (ru) Улучшенные способы лечения васкуляризированных злокачественных опухолей
ES2781974T3 (es) Anticuerpos humanos anti-VEGFR-2/KDR
RU2012131411A (ru) АНТИТЕЛА ПРОТИВ Bv8 И ИХ ПРИМЕНЕНИЕ
RU2018107693A (ru) Комбинированные виды лечения и их варианты применения и способы
JPWO2020198009A5 (enExample)